HRP20020989B1 - Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer - Google Patents

Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Info

Publication number: HRP20020989B1
Authority: HR; Croatia
Prior art keywords: farnesyl transferase; transferase inhibiting; quinoline enantiomer; annelated quinoline; annelated
Prior art date: 2000-06-22

Application number

HR20020989A

Other languages

English (en)

Croatian (hr)

Inventor

Gaston Venet Marc

Rene Angibaud Patrick

William End David

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-22

Filing date

2002-12-12

Publication date

2011-05-31

2002-12-12 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

2005-02-28 Publication of HRP20020989A2 publication Critical patent/HRP20020989A2/hr

2011-05-31 Publication of HRP20020989B1 publication Critical patent/HRP20020989B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Immunology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

HR20020989A 2000-06-22 2002-12-12 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer HRP20020989B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00202181		2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en)	2000-06-22	2001-06-13	Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number	Publication Date
HRP20020989A2 HRP20020989A2 (en)	2005-02-28
HRP20020989B1 true HRP20020989B1 (en)	2011-05-31

Family

ID=8171675

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20020989A HRP20020989B1 (en)	2000-06-22	2002-12-12	Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Country Status (34)

Country	Link
US (3)	US20030114471A1 (hu)
EP (1)	EP1296984B1 (hu)
JP (1)	JP4919575B2 (hu)
KR (2)	KR100831940B1 (hu)
CN (1)	CN1207296C (hu)
AR (1)	AR030704A1 (hu)
AT (1)	ATE294804T1 (hu)
AU (3)	AU6396201A (hu)
BG (1)	BG65894B1 (hu)
BR (1)	BRPI0111743B8 (hu)
CA (1)	CA2410232C (hu)
CZ (1)	CZ295278B6 (hu)
DE (1)	DE60110592T2 (hu)
EA (1)	EA005065B1 (hu)
EE (1)	EE04966B1 (hu)
EG (1)	EG24180A (hu)
ES (1)	ES2241830T3 (hu)
HK (1)	HK1058363A1 (hu)
HR (1)	HRP20020989B1 (hu)
HU (1)	HU229095B1 (hu)
IL (2)	IL153560A0 (hu)
IS (1)	IS2596B (hu)
JO (1)	JO2361B1 (hu)
MX (1)	MXPA02012845A (hu)
MY (1)	MY127734A (hu)
NO (1)	NO324494B1 (hu)
NZ (1)	NZ522481A (hu)
PA (1)	PA8519501A1 (hu)
PL (1)	PL209521B1 (hu)
SA (1)	SA01220349B1 (hu)
SK (1)	SK285699B6 (hu)
UA (1)	UA73572C2 (hu)
WO (1)	WO2001098302A1 (hu)
ZA (1)	ZA200210305B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003018135A1 (en)	2001-08-24	2003-03-06	Wyeth Holdings Corporation	Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
AU2003229688B2 (en)	2002-04-15	2009-07-30	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en)	2003-07-01	2005-01-06	Mitch Reponi	Methods for assessing and treating cancer
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
JP2017536403A (ja) *	2014-12-04	2017-12-07	アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	デルタ肝炎ウイルス感染の治療
EP3285768B1 (en)	2015-04-21	2020-12-30	Eiger Biopharmaceuticals, Inc.	Pharmaceutical compositions comprising lonafarnib and ritonavir
PL3277842T3 (pl)	2015-08-17	2019-12-31	Kura Oncology, Inc.	Sposoby leczenia pacjentów z nowotworem z użyciem inhibitorów farnezylotransferazy
WO2018085518A2 (en)	2016-11-03	2018-05-11	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997021701A1 (en) *	1995-12-08	1997-06-19	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998049157A1 (en) *	1997-04-25	1998-11-05	Janssen Pharmaceutica N.V.	Farnesyltransferase inhibiting quinazolinones
WO2000039082A2 (en) *	1998-12-23	2000-07-06	Janssen Pharmaceutica N.V.	1,2-annelated quinoline derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1519765A (en) *	1974-09-05	1978-08-02	Ici Ltd	Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) *	1976-12-23	1979-02-27	Pfizer Inc.	Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) *	1995-07-04	1995-09-06	Brotherwood Rodney J	Improvements in passenger carrying vehicles
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
EP0891334A1 (en)	1996-04-03	1999-01-20	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
TW591030B (en) *	1997-03-10	2004-06-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PT988038E (pt)	1997-06-02	2002-12-31	Janssen Pharmaceutica Nv	Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
IL140720A0 (en)	1998-07-06	2002-02-10	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
CZ300968B6 (cs) *	1998-07-06	2009-09-30	Janssen Pharmaceutica N. V.	Farmaceutická kompozice mající radiosenzibilizacní vlastnosti obsahující inhibitor farnesyl-protein transferasy
SK2442001A3 (en) *	1998-08-27	2002-10-08	Pfizer Prod Inc	Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof
DE69923849T2 (de) *	1998-08-27	2006-01-12	Pfizer Products Inc., Groton	Quinolin-2-on-derivate verwendbar als antikrebsmittel
US6462201B1 (en) *	1998-12-29	2002-10-08	Isp Investments Inc.	Process for the production of N-vinyl-2-pyrrolidone by vinylation
EE200100425A (et) *	1999-02-11	2002-12-16	Pfizer Products Inc.	Heteroarüül-asendatud kinoliin-2-ooni derivaadid kui vähivastased vahendid
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
AU2001231763A1 (en) *	2000-02-24	2001-09-03	Janssen Pharmaceutica N.V.	Dosing regimen
AU2001293835A1 (en)	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2002220559A1 (en)	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

2001
- 2001-05-29 JO JO200183A patent/JO2361B1/en active
- 2001-06-13 ES ES01938263T patent/ES2241830T3/es not_active Expired - Lifetime
- 2001-06-13 IL IL15356001A patent/IL153560A0/xx unknown
- 2001-06-13 HU HU0300872A patent/HU229095B1/hu unknown
- 2001-06-13 CN CNB018113788A patent/CN1207296C/zh not_active Expired - Lifetime
- 2001-06-13 US US10/312,301 patent/US20030114471A1/en not_active Abandoned
- 2001-06-13 UA UA20021210152A patent/UA73572C2/uk unknown
- 2001-06-13 CZ CZ2003114A patent/CZ295278B6/cs not_active IP Right Cessation
- 2001-06-13 NZ NZ522481A patent/NZ522481A/en not_active IP Right Cessation
- 2001-06-13 EP EP01938263A patent/EP1296984B1/en not_active Expired - Lifetime
- 2001-06-13 AU AU6396201A patent/AU6396201A/xx active Pending
- 2001-06-13 KR KR1020027014678A patent/KR100831940B1/ko active IP Right Grant
- 2001-06-13 DE DE60110592T patent/DE60110592T2/de not_active Expired - Lifetime
- 2001-06-13 MX MXPA02012845A patent/MXPA02012845A/es active IP Right Grant
- 2001-06-13 CA CA002410232A patent/CA2410232C/en not_active Expired - Lifetime
- 2001-06-13 BR BR0111743-2 patent/BRPI0111743B8/pt not_active IP Right Cessation
- 2001-06-13 WO PCT/EP2001/006747 patent/WO2001098302A1/en active IP Right Grant
- 2001-06-13 KR KR1020077026608A patent/KR100846370B1/ko active IP Right Grant
- 2001-06-13 AU AU2001263962A patent/AU2001263962B2/en not_active Expired
- 2001-06-13 JP JP2002504258A patent/JP4919575B2/ja not_active Expired - Lifetime
- 2001-06-13 SK SK50-2003A patent/SK285699B6/sk not_active IP Right Cessation
- 2001-06-13 AT AT01938263T patent/ATE294804T1/de active
- 2001-06-13 EE EEP200200695A patent/EE04966B1/xx unknown
- 2001-06-13 PL PL358918A patent/PL209521B1/pl unknown
- 2001-06-13 EA EA200300048A patent/EA005065B1/ru not_active IP Right Cessation
- 2001-06-14 PA PA20018519501A patent/PA8519501A1/es unknown
- 2001-06-20 MY MYPI20012896A patent/MY127734A/en unknown
- 2001-06-20 EG EG20010660A patent/EG24180A/xx active
- 2001-06-21 AR ARP010102954A patent/AR030704A1/es not_active Application Discontinuation
- 2001-09-10 SA SA01220349A patent/SA01220349B1/ar unknown
2002
- 2002-10-25 IS IS6590A patent/IS2596B/is unknown
- 2002-11-25 BG BG107310A patent/BG65894B1/bg unknown
- 2002-12-12 HR HR20020989A patent/HRP20020989B1/xx not_active IP Right Cessation
- 2002-12-16 NO NO20026032A patent/NO324494B1/no not_active IP Right Cessation
- 2002-12-19 IL IL153560A patent/IL153560A/en not_active IP Right Cessation
- 2002-12-19 ZA ZA200210305A patent/ZA200210305B/en unknown
2004
- 2004-02-18 HK HK04101163A patent/HK1058363A1/xx not_active IP Right Cessation
2006
- 2006-09-20 AU AU2006220405A patent/AU2006220405B2/en not_active Expired
2007
- 2007-01-31 US US11/669,587 patent/US8329714B2/en active Active
- 2007-10-29 US US11/926,741 patent/US8318753B2/en active Active

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997021701A1 (en) *	1995-12-08	1997-06-19	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998049157A1 (en) *	1997-04-25	1998-11-05	Janssen Pharmaceutica N.V.	Farnesyltransferase inhibiting quinazolinones
WO2000039082A2 (en) *	1998-12-23	2000-07-06	Janssen Pharmaceutica N.V.	1,2-annelated quinoline derivatives

Also Published As

Publication number	Publication date
NO324494B1 (no)	2007-10-29
EP1296984B1 (en)	2005-05-04
HRP20020989A2 (en)	2005-02-28
AU6396201A (en)	2002-01-02
JO2361B1 (en)	2006-12-12
NO20026032D0 (no)	2002-12-16
SK285699B6 (sk)	2007-06-07
UA73572C2 (en)	2005-08-15
EP1296984A1 (en)	2003-04-02
PL358918A1 (en)	2004-08-23
CN1437601A (zh)	2003-08-20
CZ295278B6 (cs)	2005-06-15
CA2410232C (en)	2008-10-07
CZ2003114A3 (cs)	2003-05-14
KR20030009463A (ko)	2003-01-29
JP4919575B2 (ja)	2012-04-18
PA8519501A1 (es)	2002-08-29
EG24180A (en)	2008-09-28
CN1207296C (zh)	2005-06-22
KR100831940B1 (ko)	2008-05-23
IS6590A (is)	2002-10-25
SK502003A3 (en)	2003-05-02
EA200300048A1 (ru)	2003-04-24
ZA200210305B (en)	2004-03-19
MXPA02012845A (es)	2003-05-15
IL153560A (en)	2011-06-30
KR100846370B1 (ko)	2008-07-15
HUP0300872A3 (en)	2004-11-29
AU2001263962B2 (en)	2006-07-20
AU2006220405B2 (en)	2009-05-21
DE60110592T2 (de)	2006-01-19
NZ522481A (en)	2004-09-24
US20080114009A1 (en)	2008-05-15
NO20026032L (no)	2002-12-16
BRPI0111743B1 (pt)	2019-03-26
US20030114471A1 (en)	2003-06-19
IS2596B (is)	2010-03-15
IL153560A0 (en)	2003-07-06
ES2241830T3 (es)	2005-11-01
EE04966B1 (et)	2008-02-15
US8329714B2 (en)	2012-12-11
US8318753B2 (en)	2012-11-27
BG107310A (bg)	2003-07-31
WO2001098302A1 (en)	2001-12-27
EA005065B1 (ru)	2004-10-28
BR0111743A (pt)	2003-07-08
EE200200695A (et)	2004-06-15
KR20070121847A (ko)	2007-12-27
BRPI0111743B8 (pt)	2021-05-25
AR030704A1 (es)	2003-09-03
AU2006220405A1 (en)	2006-10-12
CA2410232A1 (en)	2001-12-27
MY127734A (en)	2006-12-29
JP2004501153A (ja)	2004-01-15
HUP0300872A2 (hu)	2003-07-28
HU229095B1 (en)	2013-07-29
ATE294804T1 (de)	2005-05-15
SA01220349B1 (ar)	2007-01-23
DE60110592D1 (de)	2005-06-09
BG65894B1 (bg)	2010-04-30
PL209521B1 (pl)	2011-09-30
US20070259902A1 (en)	2007-11-08
HK1058363A1 (en)	2004-05-14

Publication	Publication Date	Title
RS51123B (sr)	2010-10-31	Aril fuzionisana azapoliciklična jedinjenja
WO2002044183A3 (en)	2003-05-22	Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2002019969A3 (en)	2002-07-11	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
YU84703A (sh)	2006-08-17	Oralni rastvor aripiprazola
RS50360B (sr)	2009-11-10	Farmaceutske formulacije derivata platine
ZA200301813B (en)	2004-06-22	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
HUP0203028A2 (hu)	2003-02-28	Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
WO2001027111A3 (de)	2001-06-14	Bicyclische imidazo-3-yl-aminderivate
NZ524138A (en)	2004-12-24	Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2002008217A3 (en)	2002-04-18	COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
HK1056118A1 (en)	2004-02-06	Medicinal compositions containing aspirin
GEP20053501B (en)	2005-05-10	Core Tablet for Controlled Release of Gliclazide after Oral Administration
WO2002015959A3 (en)	2002-08-22	Compounds and compositions for delivering active agents
HRP20020989B1 (en)	2011-05-31	Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
NZ514129A (en)	2003-04-29	Tolperison-containing, pharmaceutical preparation for oral administration
DE60102590T2 (de)	2005-04-21	Darreichungsformen zur behandlung von oralen mykosen
WO2001030331A3 (en)	2002-01-24	Therapeutic compositions including protein kinase c inhibitors
WO2004098594A3 (en)	2004-12-09	Dosage form containing pantoprazole as active ingredient
HRP20090022T3 (en)	2009-02-28	Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
JP2002542281A5 (hu)	2006-01-19
AU7866601A (en)	2001-11-20	Chiral fluoroquinolone arginine salt forms
HK1041000A1 (en)	2002-06-28	Novel pyrimidine derivatives and processes for thepreparation thereof.
CA2452432A1 (en)	2003-01-30	Active ingredient combination for the pharmacological therapy of nicotine dependence
EP1169320A4 (en)	2002-10-30	FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROL STRUCTURE AND METHOD FOR THEIR PRODUCTION

Legal Events

Date	Code	Title	Description
2005-02-28	A1OB	Publication of a patent application
2005-07-15	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-05-31	B1PR	Patent granted
2019-05-31	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20190515 Year of fee payment: 19
2020-06-26	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20200603 Year of fee payment: 20
2021-06-15	PB20	Patent expired after termination of 20 years	Effective date: 20210613